Memory clinic study on biomarkers for mild cognitive impairment
Part of Brain & nervous system, Mental health clinical trials.
This study looks at brain changes in people with mild memory problems to find early signs of Alzheimer's disease. You and a study partner can help by sharing information about your daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mild memory problems or a diagnosis of mild cognitive impairment (MCI).
- Your memory test score (MoCA) is between 18 and 28.
- You are between 55 and 80 years old.
- You have a study partner—like a family member or friend—who can regularly talk with the research team about you.
- You have a memory clinic appointment at Parkwood Institute either within the past 18 months or scheduled within the next 18 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how age affects memory and thinking, and compares people with mild memory problems, Alzheimer’s disease types, vascular dementia, and healthy controls. You may help researchers understand brain changes using thinking tests, MRI scans, and blood or spinal fluid tests.
This study uses a computer-based platform to test memory and thinking in healthy adults and in people with mild memory concerns (called aMCI). The goal is to better understand how memory changes with age and to spot early signs of Alzheimer's disease.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
This study looks for “biomarkers” (measurable signs from blood and brain tests) that may help predict who with mild cognitive impairment (MCI) could later develop dementia. Results may help doctors spot risk earlier and better plan care.
This observational study follows people with (or at risk for) Alzheimer’s-related brain changes and a comparison group without them. It uses clinic visits, cognitive testing, questionnaires, and possibly a spinal fluid test to better understand brain biomarkers and how they relate to thinking and daily life.
Hear when a new Alzheimer's Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.